Multimodal pain therapy with relapse prevention

Multimodal pain therapy with relapse prevention - MMS-RFP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00017654

Enrollment

294

Registered

2019-08-09

Start date

2019-09-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M40-M54

Interventions

Group 1: Multimodal pain therapy with relapse prevention Duration of multimodal pain therapy is four weeks Treatment on four or five working days depending on the severity of the disease Patients of S

Eligibility

Sex/Gender

All

Age

18 Years to 62 Years

Inclusion criteria

Inclusion criteria: AOK insured persons resident in the cities of Emden, Delmenhorst and Oldenburg or in the districts of Ammerland, Oldenburg, Leer, Friesland, Wittmund, Aurich, Wesermarsch, Emsland and Cloppenburg who are entitled to payment for sickness and have been unable to work for at least 28 days due to back pain (ICD M40-M54 except M45, M46 and M49).

Exclusion criteria

Exclusion criteria: Exclusion criteria are the main hospital diagnoses "psychological and behavioral disorders" (ICD F00-F99; 6 months before AU (incapacity to work)), "malignant neoplasms" (ICD C00-C97; 12 months before AU) and "injuries" (ICD S00-S99; 12 months before AU), the diagnoses "paraparesis and paraplegia, tetraparesis and tetraplegia" (ICD G82) and an age = 62 years.

Design outcomes

Primary

Measure	Time frame
Days of incapacity to work within one year after the four-week MMS intervention Work incapacity days are considered over time (1 year before/after intervention) to identify possible changes within the IG	—

Secondary

Measure	Time frame
functional capacity, quality of life, health behaviour, costs; T0: baseline/pre-intervention, T1: post-intervention (4 weeks after T0), T2: follow-up (12 months after T1) Type of survey: Questionnaires FFbH-R (Functional Questionnaire Hannover); EQ-5D; SWE scale for the general expectation of self-efficacy; PDI -Pain Disability Index; Audit-C (alcohol consumption); Heaviness of Smoking Index; Food list (LML-6); FEG - sports activity; PHQ - Patient health questionnaire	—

Measure

Time frame

functional capacity, quality of life, health behaviour, costs; T0: baseline/pre-intervention, T1: post-intervention (4 weeks after T0), T2: follow-up (12 months after T1) Type of survey: Questionnaires FFbH-R (Functional Questionnaire Hannover); EQ-5D; SWE scale for the general expectation of self-efficacy; PDI -Pain Disability Index; Audit-C (alcohol consumption); Heaviness of Smoking Index; Food list (LML-6); FEG - sports activity; PHQ - Patient health questionnaire

—

Countries

Germany

Contacts

Public ContactJulia Schmetsdorf

Institut für Epidemiologie, Sozialmedizin und Gesundheitssystemforschung Medizinische Hochschule Hannover (MHH)

Schmetsdorf.Julia@mh-hannover.de+49 511 532-4449

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 9, 2026